| 1 |
A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis |
Lupus Nephritis |
Other: Placebo|Drug: Nipocalimab|Drug: Standard-of-care treatment |
Janssen Research & Development, LLC |
Phase 2 |
NCT04883619 |
2022-09-07 |
| 2 |
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Non Small Cell Lung Cancer |
Biological: Telisotuzumab Vedotin|Drug: Docetaxel |
AbbVie |
Phase 3 |
NCT04928846 |
2022-03-25 |
| 3 |
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) |
Endometrial Neoplasms |
Biological: pembrolizumab|Drug: carboplatin|Drug: paclitaxel|Drug: docetaxel|Drug: cisplatin |
Merck Sharp & Dohme LLC|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Gynecologic Oncology Group |
Phase 3 |
NCT05173987 |
2022-02-03 |
| 4 |
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease |
Crohn's Disease |
Drug: ABBV-154|Drug: Placebo |
AbbVie |
Phase 2 |
NCT05068284 |
2022-01-31 |
| 5 |
Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA). |
Osteoarthritis, Knee |
Biological: UMC119-06-05|Device: Hyaluronic acid |
Meridigen Biotech Co., Ltd. |
Phase 1 |
NCT04893174 |
2022-01-01 |
| 6 |
Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19 |
Covid19 |
Biological: AD17002|Biological: Placebo (Formulation buffer) |
Advagene Biopharma Co. Ltd. |
Phase 1|Phase 2 |
NCT05069610 |
2021-12-15 |
| 7 |
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection |
Hepatitis B, Chronic |
Drug: JNJ-73763989|Biological: JNJ-64300535|Drug: ETV monohydrate|Drug: Tenofovir disoproxil|Drug: TAF |
Janssen Research & Development, LLC |
Phase 1 |
NCT05123599 |
2021-12-06 |
| 8 |
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs |
HIV-1 Infection |
Biological: UB-421|Drug: chidamide |
United BioPharma |
Phase 2 |
NCT05056974 |
2021-12-02 |
| 9 |
The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine |
COVID-19|Breakthrough Infection |
Biological: BNT162b2|Biological: mRNA-1273|Biological: MVC-COV1901 |
Chang Gung Memorial Hospital|Medigen Vaccine Biologics Corp. |
Phase 1|Phase 2 |
NCT05132855 |
2021-11-30 |
| 10 |
MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
RSV Infection |
Biological: MK-1654|Biological: Palivizumab|Biological: Placebo |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT04938830 |
2021-11-30 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.